How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment
NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.
Pharma & Biotech
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.